Retatrutide injection is an investigational triple-agonist peptide with no FDA approval. Learn how it works, side effects, and why no pens or pills exist.
Retatrutide injection is an investigational, once-weekly subcutaneous drug that Eli Lilly is developing for obesity and type 2 diabetes. It is not FDA-approved for any condition, so it cannot be prescribed at a US pharmacy and is only available to participants in authorized clinical trials. Anything sold online as retatrutide is an unapproved research chemical, not a tested medicine.
That distinction matters, because most of the questions people ask about this drug — dosing, side effects, whether an oral version exists — can only be answered with trial data, not with real-world prescribing information.
What Is Retatrutide Injection?
Retatrutide is a triple receptor agonist, meaning it activates three hormone receptors at once: GLP-1, GIP, and glucagon. For comparison, semaglutide (Wegovy, Ozempic) targets GLP-1 only, while tirzepatide (Zepbound, Mounjaro) targets GLP-1 and GIP.
The glucagon component is what sets retatrutide apart. Glucagon receptor activity is associated with higher energy expenditure and reduced liver fat, which researchers hope will translate into greater weight loss than current options.
In every human study so far, retatrutide has been given as a subcutaneous injection, usually once a week. It is a peptide, and peptides are broken down during digestion, which is one reason no swallowable version has been developed.
Is There a Retatrutide Pill, Pen, Tablet, or Oral Form?
No. There is no retatrutide pill, no retatrutide tablets, no retatrutide oral product, no retatrutide drops, and no branded retatrutide pen cleared for consumer use anywhere. Every formulation tested in people has been an injectable solution.
The alternative phrasing people search for is understandable — retatrutide oral and retatrutide pen sound like the convenient formats already sold for other drugs — but they describe products that do not exist.
- Injection: The only format used in human trials, given under the skin once weekly.
- Oral, pill, tablet, or drops: No human product exists; peptides like this break down in digestion.
- Pen: Retatrutide is not sold in any auto-injector or pen device. Single-dose pens exist for approved drugs such as semaglutide and tirzepatide.
Route questions are not unique to weight-loss medicine. The same debate shows up in pt-141 nasal spray vs injection discussions, where absorption and convenience drive the choice. With retatrutide, there is no route choice to make yet.
What the Clinical Trial Data Show So Far
The most-cited human data come from a Phase 2 trial published in the New England Journal of Medicine in 2023. It enrolled 338 adults with obesity and followed them for 48 weeks. Participants taking the highest dose lost an average of about 24.2% of their body weight.
Phase 3 testing is ongoing through the TRIUMPH program, and Eli Lilly has reported topline results from parts of it. Those figures have not gone through full peer review and are not a substitute for prescribing information.
| Weekly dose (Phase 2) | Average weight loss at 48 weeks |
|---|---|
| Placebo | About 2% |
| 1 mg | About 9% |
| 4 mg | About 17% |
| 8 mg | About 23% |
| 12 mg | About 24% |
Trial participants also saw improvements in waist circumference, triglycerides, and blood sugar markers. Those results came from closely monitored study conditions, and they are not a promise of what an unmonitored, self-dosed product would do.
Retatrutide vs. Approved Weight-Loss Injections
A search for peptide injections retatrutide usually leads to the same two comparisons: semaglutide and tirzepatide. Only those two can be prescribed in the United States today.
| Drug | FDA status | Receptors targeted | Route and schedule |
|---|---|---|---|
| Semaglutide (Wegovy) | Approved for chronic weight management | GLP-1 | Subcutaneous injection, weekly |
| Tirzepatide (Zepbound) | Approved for chronic weight management | GIP and GLP-1 | Subcutaneous injection, weekly |
| Retatrutide | Investigational; not approved | GIP, GLP-1, and glucagon | Subcutaneous injection, weekly (trials only) |
Regulatory status is the practical dividing line. Even FDA-cleared peptide products such as vyleesi injection reached the market only after completed trials and agency review, a bar retatrutide has not cleared.
Side Effects and Safety Considerations
The side effect profile in trials looks similar to other incretin drugs, with a few additions.
- Gastrointestinal: nausea, diarrhea, vomiting, constipation, and reduced appetite, typically worst during dose increases.
- Skin sensations: tingling or altered sensation was reported more often than with GLP-1-only drugs.
- Heart rate: small increases in resting heart rate were observed.
- Other: injection site reactions and gallbladder-related events have been reported with this drug class.
Long-term safety data do not exist yet, because the drug is still in development. Retatrutide is not appropriate during pregnancy, and anyone with a history of pancreatitis, gallbladder disease, or certain thyroid conditions should discuss risks with a clinician.
No one should self-dose an unapproved peptide based on trial percentages. Dose escalation in studies was supervised by medical teams and adjusted for tolerability.
Why Online Retatrutide Listings Are Risky
Search for retatrutide and you will find vendors selling lyophilized powder labeled for research use only. Buyers often reconstitute those vials themselves, which is where searches for bac water for injection come in. None of that supply chain is regulated for human use.
A common question is where can i buy bacteriostatic water for injection without a prescription, and brand names like hospira bacteriostatic water for injection appear frequently in those threads. Even legitimate supplies of sterile water do not turn an unapproved powder into a safe or tested medicine.
The risks include incorrect dosing, contamination, mislabeled or underdosed vials, and no way to verify what is actually inside the container. There is also no regulatory recourse if something goes wrong.
What to Do If You Are Interested in Retatrutide
- Check ClinicalTrials.gov for recruiting studies, and ask your doctor whether you might qualify.
- Review FDA-approved options such as semaglutide and tirzepatide with a clinician, since both have published safety data and covered prescribing pathways.
- Avoid unverified sellers, and never inject a product with no sterility or purity documentation.
- Bring your questions about cost, insurance, and side effects to a healthcare professional rather than to a forum.
Retatrutide may eventually become a prescription product, and late-stage results are promising. Until an approval happens, the only legitimate retatrutide injection is the one given inside a clinical trial.
Frequently Asked Questions
Is retatrutide injection available right now?
No. Retatrutide is an investigational drug and is not FDA-approved for any use in the United States, so it cannot be prescribed or sold at a pharmacy. The only legal way to receive it today is by enrolling in an authorized clinical trial.
Is there a retatrutide pill or oral form?
There is no retatrutide pill, tablet, capsule, or liquid drop product for human use. Retatrutide is a peptide that would be broken down during digestion, and every human study has used a once-weekly subcutaneous injection.
How much weight loss did retatrutide cause in trials?
In a 48-week Phase 2 trial, participants taking the 12 mg dose lost an average of about 24.2% of their body weight, compared with roughly 2% on placebo. Later-stage results have been reported but are not yet fully peer reviewed, and none of these figures apply to unapproved products sold online.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.